The Recall Desk

State

South Dakota product recalls

72,971 recalls have nationwide distribution and so reach South Dakota. 2,681 additional recalls listed South Dakota specifically in their distribution scope.

What the numbers show

Total
2,681
Critical
401
Severe
565
Most recent
2026-09-02

Of the 2,681 recalls naming South Dakota we have scored against our rubric, 401 (15%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 565 (21%) are Severe.

These figures cover only the 2,681 recalls whose distribution notice names South Dakota specifically. The 72,971 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

6976–7000 of 75652

  • ModerateFDA (Drugs)·D-0345-2025·2025-04-16

    FDA Recalls Saxagliptin Tablets Due to Manufacturing Deviations

    Glenmark Pharmaceuticals is recalling Saxagliptin 2.5mg tablets nationwide due to manufacturing quality issues. The firm initiated this voluntary recall on March 13, 2025.

    Product
    SAXAGLIPTIN — SAXAGLIPTIN (SAXAGLIPTIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0313-2025·2025-04-16

    Sofosbuvir and Velpatasvir Tablets Recalled for Defective Blister Pack Sealing

    Asegua Therapeutics is recalling 18,541 cartons of Sofosbuvir and Velpatasvir tablets nationwide due to defective blister packs that are not properly sealed, resulting in loose tablets in cartons. No illnesses or injuries have been reported.

    Product
    SOFOSBUVIR AND VELPATASVIR — SOFOSBUVIR AND VELPATASVIR (VELPATASVIR AND SOFOSBUVIR)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0342-2025·2025-04-16

    Diltiazem Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations

    Glenmark Pharmaceuticals Inc., USA is recalling Diltiazem Hydrochloride Extended-Release Capsules 12HR 120mg nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The recall is voluntary and initiated by the firm.

    Product
    DILTIAZEM HYDROCHLORIDE — DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0321-2025·2025-04-16

    Lacosamide Tablets 200mg Recalled Due to CGMP Deviations

    Glenmark Pharmaceuticals is recalling Lacosamide Tablets 200mg nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The recall is voluntary and affects specific lot numbers with expiration dates ranging from April 2025 to April 2026.

    Product
    LACOSAMIDE — LACOSAMIDE (LACOSAMIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0337-2025·2025-04-16

    Lacosamide Tablets 50mg Recalled for CGMP Manufacturing Deviations

    Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Lacosamide Tablets 50mg due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects specific lots distributed nationwide.

    Product
    LACOSAMIDE — LACOSAMIDE (LACOSAMIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Devices)·Z-1531-2025·2025-04-16

    Wayson Hydrocolloid Bandages recalled due to sterility concerns

    Medline Industries is recalling Wayson Hydrocolloid Bandages because the sterility of the devices may be compromised. Affected products include multiple models distributed nationwide and internationally.

    Product
    Wayson Hydrocolloid Models: 1) MJ BANDAGE HYDROCOLLOID HEEL OVAL 6CT, Model Number: MJ18004V2; 2) MJ BANDAGE HYDROCOLLOID ALL PURP 10CT, Model Number: MJ18005V2; 3) MJ BNDG HYDROCOLLOID FINGER TOE 8CT, Model Number: MJ76126V2; 4) WALMART,BANDAGE,HYDROCOLLOID,HEEL,6CT, Mode
    Category
    Medical Device
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0334-2025·2025-04-16

    Teriflunomide Tablets 14mg Recalled for CGMP Manufacturing Deviations

    Glenmark Pharmaceuticals Inc. is voluntarily recalling Teriflunomide 14mg tablets (Lot #17232462, expiring Nov-25) distributed nationwide due to current good manufacturing practice (CGMP) deviations discovered during production.

    Product
    TERIFLUNOMIDE — TERIFLUNOMIDE (TERIFLUNOMIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0327-2025·2025-04-16

    Fluphenazine Hydrochloride Tablets 2.5mg Recalled by Glenmark Pharmaceuticals

    Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Fluphenazine Hydrochloride Tablets 2.5mg nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The affected lot is 17232214 with expiration date September 2025.

    Product
    FLUPHENAZINE HYDROCHLORIDE — FLUPHENAZINE HYDROCHLORIDE (FLUPHENAZINE HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0352-2025·2025-04-16

    Propafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations

    Glenmark Pharmaceuticals is voluntarily recalling Propafenone Hydrochloride Extended-Release Capsules 325mg (Lot #17230767, exp. Mar-25) distributed nationwide due to Current Good Manufacturing Practice (CGMP) deviations.

    Product
    PROPAFENONE HYDROCHLORIDE — PROPAFENONE HYDROCHLORIDE (PROPAFENONE HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0344-2025·2025-04-16

    Clindamycin Hydrochloride Capsules Recalled for Manufacturing Practice Deviations

    Glenmark Pharmaceuticals Inc. USA is recalling Clindamycin Hydrochloride Capsules, USP 300mg due to CGMP deviations. The product has been distributed nationwide.

    Product
    CLINDAMYCIN HYDROCHLORIDE — CLINDAMYCIN HYDROCHLORIDE (CLINDAMYCIN HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0320-2025·2025-04-16

    Gabapentin 600mg Tablets Recalled for CGMP Deviations

    Glenmark Pharmaceuticals Inc. is voluntarily recalling Gabapentin 600mg tablets (500-count bottles) nationwide due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing.

    Product
    GABAPENTIN — GABAPENTIN (GABAPENTIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0333-2025·2025-04-16

    Solifenacin Succinate Tablets Recalled Due to Manufacturing Deviations

    Glenmark Pharmaceuticals Inc., USA is recalling Solifenacin Succinate 5mg tablets nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The recall is voluntary and affects 30-count and 90-count bottles distributed across the U.S.

    Product
    SOLIFENACIN SUCCINATE — SOLIFENACIN SUCCINATE (SOLIFENACIN SUCCINATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0328-2025·2025-04-16

    Metformin Hydrochloride Extended-Release Tablets Recalled for CGMP Deviations

    Glenmark Pharmaceuticals Inc., USA is recalling Metformin Hydrochloride Extended-Release Tablets 1000mg due to manufacturing practice deviations. The recall affects 90-count bottles distributed nationwide and is voluntary.

    Product
    METFORMIN HYDROCHLORIDE — METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0346-2025·2025-04-16

    Naproxen Sodium tablets recalled due to manufacturing compliance deviations

    Glenmark Pharmaceuticals Inc., USA is recalling Naproxen Sodium Tablets, USP 550mg nationwide due to CGMP (Current Good Manufacturing Practice) deviations identified during manufacturing. The recall affects lot #17231956 with expiration date Aug-25.

    Product
    NAPROXEN SODIUM — NAPROXEN SODIUM (NAPROXEN SODIUM)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0339-2025·2025-04-16

    Rosuvastatin Calcium Tablets Recalled Nationwide Due to Manufacturing Deviations

    Glenmark Pharmaceuticals is voluntarily recalling Rosuvastatin Calcium 40mg tablets nationwide due to manufacturing practice deviations. The recall affects specific lot numbers expiring February through June 2026.

    Product
    ROSUVASTATIN CALCIUM — ROSUVASTATIN CALCIUM (ROSUVASTATIN CALCIUM)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Food)·F-0701-2025·2025-04-16

    Desert Farms Jalapeno Mustard Recalled for Processing Defect

    The Truck Farm, LLC is recalling Desert Farms Jalapeno Mustard nationwide due to lack of an approved filed process and missing monitoring records. This is a Class II recall by the FDA.

    Product
    Desert Farms Jalapeno Mustard. Caution to refrigerate after opening. The shelf life is 2 years after the date of manufacture. It is packaged in 8 oz glass jars with a net wt. of 8.8 oz (249g). UPC code 05423401721, The Truck Farm, LLC 645 S. Alameda Las Cruces, NM, 88005.
    Category
    Food
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0353-2025·2025-04-16

    Sodium Chloride Irrigation Solution Recalled for Particulate Matter

    B. Braun Medical Inc. is recalling a sodium chloride irrigation solution due to the presence of particulate matter. The product was distributed to 12 distributors who may have further distributed it nationwide.

    Product
    SODIUM CHLORIDE — SODIUM CHLORIDE (SODIUM CHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0323-2025·2025-04-16

    Glenmark Rufinamide Tablets Recalled for Manufacturing Process Deviations

    Glenmark Pharmaceuticals is recalling Rufinamide 200mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects certain lot numbers with July 2025 expiration dates.

    Product
    RUFINAMIDE — RUFINAMIDE (RUFINAMIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0348-2025·2025-04-16

    Cetirizine HCL tablets recalled for manufacturing process deviations

    Glenmark Pharmaceuticals is voluntarily recalling Cetirizine HCL 10mg tablets distributed nationwide. The recall was initiated due to Current Good Manufacturing Practice deviations.

    Product
    CETIRIZINE HCL — CETIRIZINE HCL (CETIRIZINE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0335-2025·2025-04-16

    Drug Recall: Ranolazine Extended-Release Tablets Due to Manufacturing Deviations

    Glenmark Pharmaceuticals is recalling Ranolazine Extended-Release 1000mg tablets (Lot 17240040) nationwide due to manufacturing deviations. This is a voluntary, firm-initiated recall.

    Product
    RANOLAZINE — RANOLAZINE (RANOLAZINE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Devices)·Z-1551-2025·2025-04-16

    Siemens Atellica CH Revised C Reactive Protein Assay Software Flagging Issue

    Siemens Healthcare Diagnostics is recalling the Atellica CH Revised C Reactive Protein assay due to incorrect software flagging that may produce erroneous results.

    Product
    Atellica CH Revised C Reactive Protein (RCRP); Siemens Material Number (SMN): 11537223.
    Category
    Medical Device
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0330-2025·2025-04-16

    Glenmark Lacosamide 100mg Tablets Recalled for CGMP Deviations

    Glenmark Pharmaceuticals is recalling Lacosamide 100mg tablets nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The firm initiated this voluntary recall on March 13, 2025.

    Product
    LACOSAMIDE — LACOSAMIDE (LACOSAMIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0326-2025·2025-04-16

    Fluphenazine Hydrochloride Tablets Recalled for CGMP Deviations

    Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Fluphenazine Hydrochloride Tablets, 10mg due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects one lot distributed nationwide.

    Product
    FLUPHENAZINE HYDROCHLORIDE — FLUPHENAZINE HYDROCHLORIDE (FLUPHENAZINE HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0350-2025·2025-04-16

    Pravastatin Sodium Tablets Recalled Due to Manufacturing Practice Deviations

    Glenmark Pharmaceuticals is voluntarily recalling Pravastatin Sodium 80mg tablets due to Current Good Manufacturing Practice deviations. The nationwide recall affects specific lot numbers and remains ongoing.

    Product
    PRAVASTATIN SODIUM — PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0341-2025·2025-04-16

    Pravastatin Sodium Tablets Recalled Due to Manufacturing Deviations

    Glenmark Pharmaceuticals Inc. is recalling Pravastatin Sodium 20mg tablets nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects specific lot numbers distributed across the U.S.

    Product
    PRAVASTATIN SODIUM — PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
    Category
    Drug
    Distribution
    Distributed nationwide